Name | 5-(4-{2-[(2H3)Methyl(2-pyridinyl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione |
---|---|
Synonyms |
5-(4-{2-[(H)Methyl(2-pyridinyl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-d-2-pyridinylamino)ethoxy]phenyl]methyl]- |
Description | Rosiglitazone-d3 (BRL 49653-d3) is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3[1][2][3][4]. |
---|---|
Related Catalog | |
In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
References |
Density | 1.3±0.0 g/cm3 |
---|---|
Boiling Point | 585.0±0.0 °C at 760 mmHg |
Molecular Formula | C18H16D3N3O3S |
Molecular Weight | 360.44500 |
Flash Point | 307.6±0.0 °C |
Exact Mass | 360.13400 |
PSA | 96.83000 |
LogP | 3.02 |
Vapour Pressure | 0.0±0.0 mmHg at 25°C |
Index of Refraction | 1.642 |